We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+0.73%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$24.1B
AUM Growth
+$1.97B
Cap. Flow
+$2.05B
Cap. Flow %
8.49%
Top 10 Hldgs %
10.49%
Holding
3,709
New
1,118
Increased
953
Reduced
622
Closed
747

Sector Composition

Rank Sector Weight
1 Healthcare 20.28%
2 Financials 16.56%
3 Technology 13.74%
4 Consumer Discretionary 11.01%
5 Communication Services 4.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BCEL
3526
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
-34,465
Closed -$294K
GOEV
3527
DELISTED
Canoo Inc. Class A Common Stock
GOEV
-26
Closed -$119K
SRT
3528
DELISTED
Startek Inc.
SRT
-56,758
Closed -$405K
LTHM
3529
DELISTED
Livent Corporation
LTHM
-151,676
Closed -$2.94M
NMRD
3530
DELISTED
Nemaura Medical, Inc. Common Stock
NMRD
-62,807
Closed -$650K
EGGF.U
3531
DELISTED
EG Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third of one redeemable warrant
EGGF.U
-500,000
Closed -$5M
BURU.WS
3532
CALL
DELISTED
Nuburu, Inc. Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50
BURU.WS
-150,000
Closed -$1.5M
ARCE
3533
DELISTED
Arco Platform Limited Class A Common Shares
ARCE
-31,331
Closed -$961K
ABCM
3534
DELISTED
Abcam PLC
ABCM
-20,132
Closed -$383K
VRTV
3535
DELISTED
VERITIV CORPORATION
VRTV
-6,473
Closed -$398K
UPH.WS
3536
CALL
DELISTED
UpHealth, Inc. Warrants exercisable for one share of Common Stock at an exercise price of $115.00 per share
UPH.WS
-283,200
Closed -$1.91M
USDP
3537
DELISTED
USD PARTNERS LP
USDP
-19,840
Closed -$150K
TWNK
3538
DELISTED
Hostess Brands, Inc. Class A Common Stock
TWNK
-197,873
Closed -$3.2M
CANO
3539
DELISTED
Cano Health, Inc.
CANO
-857
Closed -$1.04M
GTH
3540
DELISTED
Genetron Holdings Limited ADS
GTH
-5,060
Closed -$306K
RVLP
3541
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
-57,958
Closed -$174K
ELYS
3542
DELISTED
Elys Game Technology, Corp. Common Stock
ELYS
-81,803
Closed -$332K
NUVA
3543
DELISTED
NuVasive, Inc.
NUVA
-46,675
Closed -$3.16M
PDCE
3544
DELISTED
PDC Energy, Inc.
PDCE
-18,011
Closed -$825K
HGEN
3545
DELISTED
HUMANIGEN, INC.
HGEN
-407,563
Closed -$7.08M
NOVN
3546
DELISTED
Novan, Inc. Common Stock
NOVN
-231,154
Closed -$2.33M
BGRY
3547
DELISTED
Berkshire Grey, Inc. Class A Common Stock
BGRY
-133,318
Closed -$1.33M
IMBI
3548
DELISTED
iMedia Brands, Inc. Class A Common Stock
IMBI
-105,728
Closed -$851K
EOCW.U
3549
DELISTED
Elliott Opportunity II Corp. Units, each consisting of one Class A ordinary share and one-fourth of one redeemable warrant
EOCW.U
-500,000
Closed -$5M
DOMA
3550
DELISTED
Doma Holdings, Inc.
DOMA
-36,334
Closed -$9.06M

Similar funds

Marshall Wace's Q3 2021 Portfolio in Review

As of Q3 2021, Marshall Wace held 3,709 positions worth $24.1B, up 8.9% from $22.1B the previous quarter. Its ten largest holdings account for 10% of the portfolio.

Marshall Wace deployed $2.05B of net new capital in Q3 2021, opening 1,118 new positions and adding to 953 existing holdings. Its largest new stake was SkinHealth Systems: 4,113,430 shares worth $107M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Biogen, an estimated $210M trimmed.

  • Marshall Wace's largest Q3 2021 buy was SkinHealth Systems: 4,113,430 shares worth $107M.
  • Marshall Wace added most to Uber in Q3 2021, an estimated $127M increase.
  • Marshall Wace's biggest Q3 2021 reduction was Biogen, cutting an estimated $210M.
  • Marshall Wace fully exited Vipshop in Q3 2021, selling an estimated $58.7M.
  • Marshall Wace's ten largest holdings make up 10% of its $24.1B portfolio in Q3 2021.
  • Marshall Wace opened 1,118 new positions and closed 747 in Q3 2021.
  • Marshall Wace's portfolio value rose 8.9% quarter-over-quarter to $24.1B.

Based on Marshall Wace's 13F filing for Q3 2021, filed 15 Nov 2021.